Glenmark Pharma Q4 Review - Better Business Mix, Operating Leverage Drives Profitability: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Glenmark Pharmaceutical Ltd. delivered marginally lower-than-expected earnings in Q4 FY21, led by subdued growth in the domestic formulation segment, flat rest of world sales, and decline in the Latin America business.
However, the outlook in the domestic formulation segment remains promising, aided by Covid-19 drugs.
The Europe business is expected to deliver healthy growth on the back of niche launches and recovery in the base business, with the easing of lockdown restrictions.
The company intends to reduce net debt through free cash flow from its core operations as well as fund raising via the Glenmark Life Sciences initial public offering.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.